Suppr超能文献

纵隔 FDG 阳性淋巴结模拟黑色素瘤进展:与伊匹单抗相关的药物诱导性类肉瘤样/淋巴结病。

Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumab.

机构信息

Dermatology, Hospital Vall d'Hebron, Barcelona, Spain

Universitat Autònoma de Barcelona, Barcelona, Spain.

出版信息

BMJ Case Rep. 2021 Jan 28;14(1):e237310. doi: 10.1136/bcr-2020-237310.

Abstract

Drug-induced sarcoidosis-like reactions (DISRs) are systemic granulomatous diseases that develop in the context of a new drug onset. Ipilimumab is an immune checkpoint inhibitor (ICI) approved for the treatment of advanced melanoma which has been associated with DISR. Differential diagnosis between tumour progression and DISR by positron emission tomography/computed tomography (PET/CT) in patients treated with an ICI can be a challenge. A 31-year-old woman was diagnosed with a stage IIIB melanoma in her back. Ipilimumab 10 mg/kg was initiated. After 1 month of finishing the treatment a routine, PET/CT showed multiple enlarged mediastinal and hilar lymph nodes FDG-positive. A transbronchial biopsy showed sarcoid-like granulomatous infiltration which favoured the diagnosis of DISR related to ipilimumab. The patient remained asymptomatic and lymphadenopathy regressed progressively after 11 months. Our work highlights the importance of differentiating DISR from tumour progression, before unnecessary changes in therapeutic strategies. PET/CT is a useful diagnostic tool for its follow-up.

摘要

药物诱导的类肉瘤样反应(DISR)是一种全身性肉芽肿性疾病,在新药物开始使用的情况下发生。易普利姆玛(Ipilimumab)是一种免疫检查点抑制剂(ICI),已被批准用于治疗晚期黑色素瘤,它与 DISR 有关。在接受 ICI 治疗的患者中,通过正电子发射断层扫描/计算机断层扫描(PET/CT)鉴别肿瘤进展和 DISR 可能具有挑战性。一名 31 岁女性被诊断为背部 IIIB 期黑色素瘤。开始给予易普利姆玛 10 mg/kg。治疗结束后 1 个月,常规 PET/CT 显示多个纵隔和肺门增大的淋巴结 FDG 阳性。经支气管活检显示类肉瘤样肉芽肿性浸润,这支持与易普利姆玛相关的 DISR 诊断。患者无症状,淋巴结病在 11 个月后逐渐消退。我们的工作强调了在不必要改变治疗策略之前,区分 DISR 与肿瘤进展的重要性。PET/CT 是一种有用的随访诊断工具。

相似文献

3
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Eur J Cancer. 2020 May;131:18-26. doi: 10.1016/j.ejca.2020.02.024. Epub 2020 Apr 2.
4
Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Chest. 2016 May;149(5):e133-6. doi: 10.1016/j.chest.2015.10.082.
6
Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
J Oncol Pharm Pract. 2017 Dec;23(8):620-624. doi: 10.1177/1078155216667635. Epub 2016 Sep 2.
7
Can benign lymphoid tissue changes in F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
Cancer Immunol Immunother. 2019 Feb;68(2):297-303. doi: 10.1007/s00262-018-2279-9. Epub 2018 Nov 26.
8
Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Medicine (Baltimore). 2019 Jul;98(29):e16417. doi: 10.1097/MD.0000000000016417.

引用本文的文献

1
Drug-Induced Sarcoid-like Reactions Associated to Targeted Therapies and Biologic Agents.
Diagnostics (Basel). 2025 Jun 29;15(13):1658. doi: 10.3390/diagnostics15131658.
4
Suspected immune checkpoint inhibitor-induced pulmonary sarcoid reaction in metastatic renal cell carcinoma.
Clin Case Rep. 2022 Jul 11;10(7):e5960. doi: 10.1002/ccr3.5960. eCollection 2022 Jul.
5
Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report.
Int J Hematol. 2022 Aug;116(2):302-306. doi: 10.1007/s12185-022-03312-0. Epub 2022 Feb 24.

本文引用的文献

2
Drug-Induced Sarcoidosis-Like Reactions.
Chest. 2018 Sep;154(3):664-677. doi: 10.1016/j.chest.2018.03.056. Epub 2018 Apr 24.
4
Sarcoid-like reactions in patients receiving modern melanoma treatment.
Melanoma Res. 2018 Jun;28(3):230-236. doi: 10.1097/CMR.0000000000000437.
6
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
N Engl J Med. 2016 Nov 10;375(19):1845-1855. doi: 10.1056/NEJMoa1611299. Epub 2016 Oct 7.
7
Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
J Oncol Pharm Pract. 2017 Dec;23(8):620-624. doi: 10.1177/1078155216667635. Epub 2016 Sep 2.
8
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.
PLoS One. 2016 Jul 29;11(7):e0160221. doi: 10.1371/journal.pone.0160221. eCollection 2016.
9
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验